Answers · By Hugh Donatello, Atlas Bio · Updated 2026-10-31

How Do You Verify an AI Agent's Answer Before a Research Team Relies on It?

How do you verify an AI agent's answer before a research team relies on it? Check the claims, not the prose. Break the answer into individual claims, confirm that each cited source supports that specific claim, recompute every number from the source, search deliberately for evidence that contradicts the conclusion, and then send it to a human reviewer whose depth matches what the decision puts at risk. A claim that cannot be checked is marked unverified, and any conclusion that depends on it is held rather than passed.

Why a fluent answer is not a verified one

An AI agent's answer usually arrives well written, confidently worded and with citations attached. None of those properties is evidence that it is right. NIST's generative AI profile (NIST AI 600-1, July 2024) describes confabulation as a phenomenon in which generative AI systems generate and confidently present erroneous or false content, and warns that outputs may also include confabulated logic or citations that purport to justify or explain the system's answer. The same document names automation bias, excessive deference to automated systems, as a risk that can make confabulation worse.

An invented paper is caught as soon as someone looks it up. The harder failure to catch is a real paper cited for something it does not say: an effect from one population reported as if it applied to all, a relative number reported as an absolute one, or a single observational result presented as settled. Those errors survive a quick read because every citation resolves.

This page covers checking one answer before people act on it. It is not the same task as validating the agent itself, which asks whether the system is fit for its intended use and is covered in Atlas Bio's answer on validating an AI agent used in a GxP process. It is also separate from the evidence standard a prediction should meet, which is covered in Atlas Bio's answer on what evidence AI biology predictions should meet. This page is general guidance, not legal or regulatory advice.

The five-stage check

Each stage catches a different kind of error, and the stages run in order because each depends on the one before. A source cannot be checked until the claim it supports has been isolated, and a reviewer cannot judge a conclusion until its numbers have been reproduced.

StageWhat the checker doesWhat counts as a failureWho or what can do it
1. Extract the claimsSplits the answer into individual, checkable statements and tags each as a sourced fact, a number, an inference or a recommendation; marks the claims the conclusion depends onA factual claim with no source; a conclusion that rests on a claim nobody can identifyA separate model or script can draft the list; a person confirms it for consequential answers
2. Confirm the source supports the specific claimOpens the cited source itself, not the agent's summary of it, and finds the passage; checks the population, species, model system, assay, endpoint, direction and size of effectSource missing or not found; passage absent; claim broader, stronger or in a different setting than the sourceA person with the source open, or a second model with the full text, with a person checking what it flags
3. Recompute the numbersRecalculates every derived figure from the source values with a deterministic tool: units, denominators, relative versus absolute effects, confidence intervalsA number that cannot be reproduced from the source, or that changes meaning (for example a ratio reported as a difference)A calculator, script or notebook, not the language model that wrote the answer
4. Challenge with contradicting evidenceSearches deliberately for null results, failed replications, retractions and findings in other species or populations; asks what result would make the conclusion wrongContradicting evidence the answer omitted; a conclusion stronger than the evidence class allowsAn independent reviewer or a separately prompted agent; the search terms and results are recorded even when nothing is found
5. Risk-proportionate human reviewA person with the authority to reject the answer reviews the flags and decides whether it can be relied on, at a depth set by what the decision puts at riskApproval given without the flagged claims and their sources in front of the reviewer; no record of the decision or its reasonA named scientist; for high-consequence decisions, a senior reviewer who signs the record

What each stage is looking for

Extracting claims turns a paragraph into a checklist. A one-page target-validation summary can contain many separate assertions, and only some of them carry the conclusion. Marking which ones do tells the checker where to spend effort and tells the reviewer which failures matter.

NIST's suggested actions for generative AI point at this stage. Among its suggested actions, NIST AI 600-1 includes reviewing and verifying sources and citations in generative AI outputs during pre-deployment risk measurement and ongoing monitoring (MS-2.5-003), and deploying and documenting fact-checking techniques to verify the accuracy and veracity of information generated by generative AI systems, especially when the information comes from multiple or unknown sources (MP-2.3-003). In biology the check has to go past whether the paper exists to whether it says this, in this setting. A mouse result cited for a human claim, or a cell-line result cited for a tissue claim, fails even though the citation is real.

Recomputing numbers catches the errors that pass every other stage. Language models restate numbers fluently and can convert them incorrectly. The recomputation should be done by a tool whose arithmetic does not depend on a model's wording, and the checker should record the source value, the calculation and the result.

Challenging the conclusion is the easiest stage to skip, because the answer looks complete. An agent asked to summarize the evidence for a target will tend to find evidence for it. The challenge reverses the question: what is the strongest evidence against this, and is it in the answer? Atlas Bio's answer on agentic AI for drug-target validation describes this as enumerating competing hypotheses rather than defending the first one.

Human review comes last so that the reviewer works from the flags rather than from the prose. A reviewer shown a clean summary tends to approve it; a reviewer shown the three claims that failed stages 2 to 4 has something specific to decide.

When evidence is missing, the answer fails safe

Every check produces some claims that cannot be settled: the source is behind a paywall, the cited dataset is not public, the number cannot be reproduced, or the claim has no source at all. The rule that makes the process safe is that an unsettled claim is never treated as a passed one. It is labelled unverified, and anything that depends on it is held until a person decides.

In practice that means four things. The agent's answer is returned with each unverified claim marked, not quietly removed, so the reader can see the gap. A conclusion that depends on an unverified claim is downgraded to a hypothesis or held. The decision to rely on the answer anyway is taken by a named person and recorded with the reason. And the verification record keeps, for each claim, where in the source it was checked, the result, who or what checked it, the date and the version of the answer checked.

The same idea appears in draft GMP guidance for a narrower kind of model. The European Commission's draft Annex 22 on artificial intelligence, whose public consultation ran from 7 July to 7 October 2025, says that if a model's confidence score is very low, it should be considered whether the model should flag the outcome as undecided rather than making potentially unreliable predictions or classifications (section 9.2). The consultation draft covers static, deterministic models and states that it does not apply to generative AI and large language models, so it is an analogy for agent output, not a requirement that governs it. As of October 2026 the annex has not been adopted, and its final text, including how it treats generative AI and large language models, may change. The principle carries over: an honest undecided is worth more than a confident guess.

Worked example: checking a target-validation summary

The summary below was written by Atlas Bio for this page to illustrate the method. It is not output from a real engagement or a real agent run, and the errors in it were placed deliberately. The two published studies it cites are real, and the corrections are taken from their abstracts. The example tests whether the summary supports its own statements; it is not an assessment of PCSK9 as a target. The illustrative summary reads: PCSK9 is a strongly validated target for reducing coronary heart disease. Loss-of-function variants in PCSK9 reduce coronary heart disease risk by 88% (Cohen et al., NEJM 2006), a precise estimate from a large cohort. Genetic support of this kind raises the probability of clinical success by 2.6 percentage points (Minikel et al., Nature 2024). Lifelong loss of PCSK9 function has no known adverse effects.

Stage 1 extracts five claims. The table shows what the later stages find.

Claim in the summaryStage that catches itWhat the check findsCorrected or held text
Loss-of-function PCSK9 variants reduce coronary heart disease risk by 88%2. Source supportCohen et al. report the 88% reduction for nonsense mutations in PCSK9 among 3,363 Black participants in the Atherosclerosis Risk in Communities study, of whom 2.6% carried them. Among 9,524 White participants, a different sequence variation was associated with a 15% reduction in LDL cholesterol and a 47% reduction in coronary heart disease risk. The summary turned one variant class in one population into a general effect.In ARIC, PCSK9 nonsense mutations in Black participants were associated with an 88% lower risk of coronary heart disease over 15 years; a different PCSK9 variant in White participants was associated with a 47% lower risk.
The 88% figure is a precise estimate2. Source supportThe same abstract gives a hazard ratio of 0.11 with a 95% confidence interval of 0.02 to 0.81. The effect is large, but the interval is wide.Large but imprecise: hazard ratio 0.11 (95% CI 0.02 to 0.81).
Genetic support raises the probability of clinical success by 2.6 percentage points3. RecomputeMinikel et al. estimate that the probability of success for drug mechanisms with genetic support is 2.6 times greater than those without. That is a ratio, not a difference; an absolute figure would need a baseline success rate the summary does not give.Drug mechanisms with genetic support had an estimated 2.6-fold higher probability of success; the authors report that this varies by therapy area and development phase.
Lifelong loss of PCSK9 function has no known adverse effects1. Extraction, then fail-safeA factual claim with no source. It cannot pass stage 2.Marked unverified and removed from the conclusion pending a sourced review of the safety evidence. This page makes no claim about PCSK9 safety either way.
PCSK9 is a strongly validated target4. ChallengeThe cited evidence is an observational genetic association with one outcome plus a cross-target statistic. The conclusion is stronger than the evidence the summary actually presents.Held as a conclusion of this summary until the reviewer states the evidence class and the record shows the search for contradicting evidence, including its terms, even if nothing was found. The hold concerns this summary's support, not PCSK9's standing as a target; a full check would also record relevant evidence the summary omitted, including clinical evidence.

How much human review is enough

Not every answer needs the same depth of review, and pretending otherwise produces rubber-stamping. The useful question is how much a decision will rest on this answer and what happens if the answer is wrong.

FDA's draft guidance of January 2025, still a draft as of October 2026, on AI to support regulatory decision-making for drugs and biological products uses those two factors. It defines model risk as a combination of model influence, the contribution of the evidence derived from the AI model relative to other contributing evidence, and decision consequence, the significance of an adverse outcome resulting from an incorrect decision. The guidance states that it does not address the use of AI models in drug discovery, or AI used for operational efficiencies such as internal workflows and drafting a regulatory submission that do not affect patient safety, drug quality or the reliability of study results. For most internal agent answers the logic is therefore borrowed, not required. In the guidance, model risk sets the rigor of the credibility assessment; used by analogy, it is a defensible basis for scaling review depth.

For an answer used to brainstorm or to rank internal hypotheses, a scientist reviews the claims that failed stages 2 to 4. For an answer that will shape an experiment plan or a go or no-go recommendation, the reviewer reads every load-bearing claim with the sources open. For an answer that will commit significant budget, enter a regulated record or support a regulatory submission, a named senior reviewer with authority to reject it reviews the full verification record and the decision is recorded.

Where output enters GMP work, the consultation draft of Annex 22 is more specific, subject to the caveat above that its final text may change. It says generative AI and large language models should not be used in critical GMP applications, and that in non-critical GMP applications, which do not have direct impact on patient safety, product quality or data integrity, personnel with adequate qualification and training should always be responsible for ensuring that the outputs are suitable for the intended use, a human-in-the-loop, and that the annex's principles may be considered where applicable (section 1). For the static, deterministic models the draft does cover, where a model gives an input to a decision made by a human operator and the effort to test the model has been diminished, it asks that records be kept from this process; depending on the criticality of the process and the level of testing, that may imply a consistent review and/or test of every output, according to a procedure (section 10.5). That section is written for in-scope models, not for agent output, but it shows how regulators link reduced testing to more review. Whether a given workflow is GxP, and which records follow, is a decision for your organization under your quality function's oversight.

Verification, pre-registration and evidence standards

Verification and pre-registration answer different questions. Verification asks whether an answer is faithful to the evidence that exists today. Pre-registration asks whether a prediction, locked before the outcome was known, turned out to be right. Atlas Bio's answer on prediction pre-registration in AI biology covers the second. A team that relies on an agent's predictions needs both: verification so that the reasoning is sound now, and pre-registration so that the agent's track record can be measured later.

Atlas Bio's answer on what evidence AI biology predictions should meet sets out the standard the verified answer is held to: the evidence class of each claim, uncertainty stated with its drivers, and performance outside the training distribution reported alongside the headline number. Verification checks that an answer meets that standard. It does not make the biology true. Confirmatory experiments still decide whether a target is real.

Atlas Bio applies a version of this check to agent-drafted work it publishes. Status, October 2026. In use in Atlas Bio's own operations today, not yet with a client: a separate verification step that checks agent work before Atlas publishes it, and a hold that stops a task the system cannot settle until a person decides. In pilot on selected analyses Atlas publishes: a multi-node reasoning audit that looks for causal, contradiction, confidence and time-order errors; no run log shows it applied to every output. In pilot in one study: earlier versions of the prediction files locked with SHA-256 hashes before readout; the latest version's hash is not yet recorded, and lock dates come from Atlas's own record rather than a third-party timestamp. Planned, design only with no code yet: linking each conclusion in the record to the evidence behind it. None of these has been independently assessed. Decisions on GxP scope and validation stay with your organization, under your quality function's oversight.

Can another AI model do the verification?

Partly. A second model or a script can extract claims, find passages in full-text sources and recompute numbers, and that saves time. It should be separate from the agent that wrote the answer, because a checker using the same model and the same prompt can share its blind spots. The final decision to rely on the answer stays with a person.

Is verifying an answer the same as validating the agent?

No. Validation shows the agent is fit for its intended use across many cases and is done before and during deployment. Verification checks one specific answer before people rely on it. A validated agent can still produce a wrong answer, which is why both exist.

What if a cited source is paywalled or unavailable?

The claim is marked unverified until someone with access checks it. If the conclusion depends on that claim, the answer is held or the conclusion is downgraded to a hypothesis. A citation that cannot be opened is not evidence for the reader.

Does every answer need all five stages?

Every answer that people will act on needs claim extraction and source checks. How deep the number checks, the search for contradicting evidence and the human review go should scale with how much the decision rests on the answer and what a wrong answer would cost.

Does a verified answer mean the conclusion is correct?

No. Verification shows the answer accurately reflects its sources and that the obvious contradicting evidence was looked for. The sources themselves can be wrong or incomplete, and the biology is settled by experiment, not by checking a summary.

  1. NIST AI 600-1, Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile (July 2024)
  2. FDA draft guidance: Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (January 2025)
  3. FDA draft guidance, full text (PDF)
  4. European Commission: EudraLex Volume 4, draft Annex 22 Artificial Intelligence (consultation version, 2025)
  5. European Commission: Stakeholders' consultation on EudraLex Volume 4 - Chapter 4, Annex 11 and new Annex 22 (2025)
  6. European Commission: EudraLex Volume 4, Good Manufacturing Practice guidelines (current annexes)
  7. Cohen JC et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006 (PubMed abstract)
  8. Minikel EV et al. Refining the impact of genetic evidence on clinical success. Nature 2024 (PubMed abstract)

Talk to Atlas Bio.

Sponsors, researchers and clinicians: tell us the decision you are trying to make and we will show what the platform can and cannot answer.

Contact Us →